|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2003-1-21
|
|
pubmed:abstractText |
The effects of 17 beta-estradiol, dihydrodydrogesterone, tamoxifen and cyclophosphamide upon parameters of cell maturation (Mucine1 expression), cell proliferation (Cyclin D1 expression) and apoptosis (loss of nuclear DNA) were studied in estrogen receptor positive (ER+) and negative (ER-) human breast cancer cells. Tamoxifen was the most potent inducer of apoptosis in ER+ and ER- breast cancer cells. 17 beta-estradiol in a concentration of 10(-6) M induced proliferation in ER+ cells after 144 h. incubation, while equimolar co-incubation with dihydrodydrogesterone prevented this effect and even induced a significant increase of cell death. It is speculated that the continuous use of combined 17 beta-estradiol plus dihydrodydrogesterone might be given as hormone replacement therapy without increased risk of breast cancer and even may reduce the relapse rate in breast cancer patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Alkylating,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Hormonal,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin D1,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Dydrogesterone,
http://linkedlifedata.com/resource/pubmed/chemical/Estradiol,
http://linkedlifedata.com/resource/pubmed/chemical/Mucins,
http://linkedlifedata.com/resource/pubmed/chemical/Progesterone Congeners,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen,
http://linkedlifedata.com/resource/pubmed/chemical/Tamoxifen
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0304-3835
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
10
|
|
pubmed:volume |
190
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
113-8
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12536084-Antineoplastic Agents, Alkylating,
pubmed-meshheading:12536084-Antineoplastic Agents, Hormonal,
pubmed-meshheading:12536084-Apoptosis,
pubmed-meshheading:12536084-Breast Neoplasms,
pubmed-meshheading:12536084-Cell Death,
pubmed-meshheading:12536084-Cell Division,
pubmed-meshheading:12536084-Cell Nucleus,
pubmed-meshheading:12536084-Cyclin D1,
pubmed-meshheading:12536084-Cyclophosphamide,
pubmed-meshheading:12536084-Dydrogesterone,
pubmed-meshheading:12536084-Estradiol,
pubmed-meshheading:12536084-Humans,
pubmed-meshheading:12536084-Mucins,
pubmed-meshheading:12536084-Progesterone Congeners,
pubmed-meshheading:12536084-Receptors, Estrogen,
pubmed-meshheading:12536084-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:12536084-Tamoxifen,
pubmed-meshheading:12536084-Time Factors,
pubmed-meshheading:12536084-Tumor Cells, Cultured
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
In vitro effects of estradiol, dydrogesterone, tamoxifen and cyclophosphamide on proliferation vs. death in human breast cancer cells.
|
|
pubmed:affiliation |
Department of Obstetrics and Gynecology, Medisch Spectrum Twente Hospital Group, PO Box 50000, 7500 KA The, Enschede, Netherlands. hfranke@xs4all.nl
|
|
pubmed:publicationType |
Journal Article
|
